Why this chain matters

Compugen Ltd. (CGEN) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when CGEN performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to CGEN's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • Grande Group Limited (GRAN) - confidence 85%.
  • Sentage Holdings Inc. (SNTG) - confidence 85%.
  • Sanofi (SNYNF) - confidence 72%.
  • Sanofi (SNYNF) - confidence 72%.
  • Super Hi International Holding Ltd. (HDL) - confidence 62%.
  • Kyivstar Group Ltd. (KYIV) - confidence 62%.
  • Rich Sparkle Holdings Limited (ANPA) - confidence 62%.
  • VNET Group, Inc. (VNET) - confidence 62%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • AstraZeneca PLC (AZN) - confidence 92%.
  • GILEAD (GILEAD) - confidence 92%.
  • AstraZeneca PLC (AZN) - confidence 92%.
  • Gilead Sciences, Inc. (GILD) - confidence 85%.
  • Gilead Sciences, Inc. (GILD) - confidence 85%.
  • PureTech Health plc (PRTC) - confidence 72%.
  • Nasus Pharma Ltd. (NSRX) - confidence 72%.
  • Sanofi (SNYNF) - confidence 72%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • Compugen Ltd.: Reciprocal relationship from AZN graph: Reciprocal relationship from CGEN graph: Under the terms of the license agreement, as amended (including most recently as December 16, 2025), we provided an exclusive license to AstraZeneca to use our monospecific antibo
  • Compugen Ltd.: Under the terms of the license agreement, as amended (including most recently as December 16, 2025), we provided an exclusive license to AstraZeneca to use our monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and
  • Compugen Ltd.: Under the terms of the license agreement, we granted Gilead an exclusive license under our preclinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercial
  • CGEN-OWNER-SILVERARC-CAPITAL-MANAGEMENT-LLC: 13F overlay lists SILVERARC CAPITAL MANAGEMENT, LLC as top holder; 79 tracked holders.
  • Grande Group Limited: Reciprocal relationship from GRAN graph: nformation Our principal executive offices are located at Suite 2701, 27/F, Tower 1, Admiralty Center, 18 Harcourt Road, Admiralty, Hong Kong. Our registered office in the BVI is at Vistra Corporate Services Centre, Wic

Who benefits and who is exposed

If Compugen Ltd. outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If CGEN struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

How to read the signal

A compact graph can still be useful when the named counterparties are specific and the evidence is direct. Investors should read each relationship as a working hypothesis about exposure, then compare it with revenue mix, segment performance, margin pressure, and management commentary in the next filing cycle.

The strongest signals usually have three traits: a named counterparty, a clear commercial role, and repeated language over time. A one-off mention is weaker. A relationship tied to manufacturing, purchasing, licensing, distribution, or customer concentration is stronger because it can affect revenue durability, operating leverage, or execution risk.

For Compugen Ltd., the current graph gives analysts a starting map rather than a final conclusion. The supplier side points to operating dependencies. The customer side points to demand dependencies. The evidence trail shows which edges deserve deeper work before they are used in a trade or portfolio risk review.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.